Especialización en Reumatología
URI permanente para esta comunidad
Noticias
Navegar
Examinando Especialización en Reumatología por Autor "Aza, Anggie"
Mostrando 1 - 2 de 2
Resultados por página
Opciones de ordenación
Publicación Acceso abierto Emergency arising from patients' fear of taking antimalarials during these COVID-19 times: are antimalarials as unsafe for cardiovascular health as recent reports suggest?(Alianza Europea de Asociaciones de Reumatología (EULAR) y BMJ, 2020-06-24) Santos Moreno, Pedro; Buitrago García, Diana; Villarreal, Laura; Aza, Anggie; Cabrera, Michael; Rivero, Wilberto; Rojas Villarraga, AdrianaWe read with interest the paper of Graef et al recently published in your journal about the situation resulting from the massive use of antimalarials for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2/COVID-19), despite the fact that the evidence is controversial and there are concerns about its possible cardiotoxicity, leaving rheumatic patients who use them in a position of vulnerability due to medication shortages.1 In the past few weeks, several papers have been published about the efficacy and safety of the antimalarials chloroquine (CLQ) and hydroxychloroquine (HCLQ) for the treatment of the different phases of infection by SARS-CoV-2/COVID-19, and the data are controversial. However, it is striking that some studies report high rates of cardiovascular events (CVEs) associated mainly with cardiac arrhythmias.2 . These findings of adverse CVEs reported in the aforementioned studies have unfortunately led to the emergency in this group of patients around fear of chronic use of antimalarials, and many users are abandoning these medications, which implies great clinical risk due to relapses that may appear.3 On the other hand, the massive use of antimalarials for COVID-19 has resulted in medication shortages in some settings with potential consequences to patients users. Antimalarials have been used for several decades for the treatment of malaria and some autoimmune diseases, mainly rheumatoid arthritis (RA) and lupus, with great utility and efficacy, and also great safety at conventional doses (250mg per day of CLQ and 200–400mg per day of HCLQ).Publicación Acceso abierto Experience of telemedicine use in a big cohort of patients with rheumatoid arthritis during COVID-19 pandemic(BMJ Publishing Group, 2021-05) Santos-Moreno, Pedro; Chavez-Chavez, Josefina; Hernández-Zambrano, Sandra Milena; Rivera-Triana, Diana Patricia; Castiblanco-Montañez, Ruth Alexandra; Aza, Anggie; Buitrago-García, Diana; Villarreal, Laura; Rojas-Villarraga, AdrianaWe have read with interest the work of Bozzalla-Cassione et al1 published recently in your journal regarding the implementation of a telemedicine programme for patients with lupus in northern Italy. It is logical to suppose that the risk of patients with rheumatic diseases of having a more severe clinical course if they become infected with the COVID-19 infection is very high; however, although some of the reports show that there seems to be a low incidence of COVID-19 infection in patients with rheumatic disease, collaborative work with large cohorts is needed, which could show us the real incidence of COVID-19 infection in these patients and what happens with the establishment of telemedicine programmes.2–6 We show an experience in a specialised centre in Bogota, Colombia; currently, we have a cohort of 5597 patients with rheumatoid arthritis (RA) in exclusively ambulatory care. On 12 March 2020, in Colombia, the health emergency by COVID-19 was established and a week later the Ministry of Health ordered the outpatient care procedure for the population in isolation. From that moment on, our institution, carrying out the proper logistical and legal processes, proceeded to convert its ambulatory care services into care through telemedicine.